Alzheimer Hastalığında NHE6: Endozomal pH Düzenlenmesi ve Moleküler Mekanizmalar

Rostagno, A. A. Pathogenesis of Alzheimer’s Disease. Int. J. Mol. Sci. 24, (2023).

Orlowski, J. & Grinstein, S. Na+/H+ exchangers. Compr. Physiol. 1, 2083–2100 (2011).

Pedersen, S. F. & Counillon, L. The SLC9A-C Mammalian Na+/H+ Exchanger Family: Molecules, Mechanisms, and Physiology. Physiol. Rev. 99, 2015–2113 (2019).

Casey, J. R., Grinstein, S. & Orlowski, J. Sensors and regulators of intracellular pH. Nat. Rev. Mol. Cell Biol. 11, 50–61 (2010).

Chesler, M. Regulation and modulation of pH in the brain. Physiol. Rev. 83, 1183–1221 (2003).

Sinning, A. & Hübner, C. A. Minireview: pH and synaptic transmission. FEBS Lett. 587, 1923–1928 (2013).

Li, P. A. & Siesjö, B. K. Role of hyperglycaemia-related acidosis in ischaemic brain damage. Acta Physiol. Scand. 161, 567–580 (1997).

Schuchmann, S. et al. Experimental febrile seizures are precipitated by a hyperthermia-induced respiratory alkalosis. Nat. Med. 12, 817–823 (2006).

Patak, J., Faraone, S. V. & Zhang-James, Y. Sodium hydrogen exchanger 9 NHE9 (SLC9A9) and its emerging roles in neuropsychiatric comorbidity. Am. J. Med. Genet. B Neuropsychiatr. Genet. 183, 289–305 (2020).

Nakamura, N., Tanaka, S., Teko, Y., Mitsui, K. & Kanazawa, H. Four Na+/H+ exchanger isoforms are distributed to Golgi and post-Golgi compartments and are involved in organelle pH regulation. J. Biol. Chem. 280, 1561–1572 (2005).

Ohgaki, R. et al. The Na+/H+ exchanger NHE6 in the endosomal recycling system is involved in the development of apical bile canalicular surface domains in HepG2 cells. Mol. Biol. Cell 21, 1293–1304 (2010).

Ouyang, Q. et al. Christianson syndrome protein NHE6 modulates TrkB endosomal signaling required for neuronal circuit development. Neuron 80, 97–112 (2013).

Roxrud, I., Raiborg, C., Gilfillan, G. D., Strømme, P. & Stenmark, H. Dual degradation mechanisms ensure disposal of NHE6 mutant protein associated with neurological disease. Exp. Cell Res. 315, 3014–3027 (2009).

Malo, M. E. & Fliegel, L. Physiological role and regulation of the Na+/H+ exchanger. Can. J. Physiol. Pharmacol. 84, 1081–1095 (2006).

Kittler, J. T. et al. Constitutive endocytosis of GABAA receptors by an association with the adaptin AP2 complex modulates inhibitory synaptic currents in hippocampal neurons. J. Neurosci. 20, 7972–7977 (2000).

Hanley, J. G. The Regulation of AMPA Receptor Endocytosis by Dynamic Protein-Protein Interactions. Front. Cell. Neurosci. 12, (2018).

Kurosinski, P., Guggisberg, M. & Götz, J. Alzheimer’s and Parkinson’s disease - Overlapping or synergistic pathologies? Trends Mol. Med. 8, 3–5 (2002).

Mignot, C. et al. Novel mutation in SLC9A6 gene in a patient with Christianson syndrome and retinitis pigmentosum. Brain Dev. 35, 172–176 (2013).

Pescosolido, M. F. et al. Complex Neurological Phenotype in Female Carriers of NHE6 Mutations. Mol. Neuropsychiatry 5, 98–108 (2019).

Jiang, T., Yu, J.-T., Tian, Y. & Tan, L. Epidemiology and etiology of Alzheimer’s disease: from genetic to non-genetic factors. Curr. Alzheimer Res. 10, 852–867 (2013).

Ross, C. A. & Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 10 Suppl, S10 (2004).

Bonifacino, J. S. & Traub, L. M. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu. Rev. Biochem. 72, 395–447 (2003).

Haung Yu, W. et al. Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer’s disease. J. Cell Biol. 171, 87–98 (2005).

Cirrito, J. R. et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58, 42–51 (2008).

Sun, J. & Roy, S. The physical approximation of APP and BACE-1: A key event in alzheimer’s disease pathogenesis. Dev. Neurobiol. 78, 340–347 (2018).

Strømme, P. et al. X-linked Angelman-like syndrome caused by Slc9a6 knockout in mice exhibits evidence of endosomal-lysosomal dysfunction. Brain 134, 3369–3383 (2011).

Lee, Y. et al. Early lysosome defects precede neurodegeneration with amyloid-β and tau aggregation in NHE6-null rat brain. Brain 145, 3187–3202 (2022).

Prasad, H. & Rao, R. The Na+/H+ exchanger NHE6 modulates endosomal pH to control processing of amyloid precursor protein in a cell culture model of Alzheimer disease. J. Biol. Chem. 290, 5311–5327 (2015).

Prasad, H. & Rao, R. Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH. Proc. Natl. Acad. Sci. U. S. A. 115, E6640–E6649 (2018).

Fernandez, M. A. et al. Loss of endosomal exchanger NHE6 leads to pathological changes in tau in human neurons. Stem Cell Reports 17, 2111–2126 (2022).

De-Paula, V. J., Radanovic, M., Diniz, B. S. & Forlenza, O. V. Alzheimer’s Disease. Subcell. Biochem. 65, 329–352 (2012).

Ferretti, M. T. et al. Sex differences in Alzheimer disease — the gateway to precision medicine. Nature Reviews Neurology 2018 14:8 14, 457–469 (2018).

Livingston, G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet 396, 413–446 (2020).

Yiannopoulou, K. G. & Papageorgiou, S. G. Current and Future Treatments in Alzheimer Disease: An Update. J. Cent. Nerv. Syst. Dis. 12, (2020).

Haines, J. L. Alzheimer Disease: Perspectives from Epidemiology and Genetics. Journal of Law, Medicine & Ethics 46, 694–698 (2018).

2019 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia 15, 321–387 (2019).

Mucke, L. Alzheimer’s disease. Nature 2009 461:7266 461, 895–897 (2009).

Piaceri, I., Nacmias, B. & Sorbi, S. Genetics of familial and sporadic Alzheimer’s disease. Frontiers in Bioscience - Elite 5 E, 167–177 (2013).

Tiwari, S., Atluri, V., Kaushik, A., Yndart, A. & Nair, M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int. J. Nanomedicine 14, 5541–5554 (2019).

Lanoiselée, H. M. et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med. 14, e1002270 (2017).

Gunnarsson, L. G. & Bodin, L. Occupational Exposures and Neurodegenerative Diseases—A Systematic Literature Review and Meta-Analyses. International Journal of Environmental Research and Public Health 2019, Vol. 16, Page 337 16, 337 (2019).

Huynh, T. P. V., Davis, A. A., Ulrich, J. D. & Holtzman, D. M. Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins: Thematic Review Series: ApoE and Lipid Homeostasis in Alzheimer’s Disease. J. Lipid Res. 58, 824–836 (2017).

Najm, R., Jones, E. A. & Huang, Y. Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease. Molecular Neurodegeneration 2019 14:1 14, 1–13 (2019).

Gordon, B. A. et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: a longitudinal study. Lancet Neurol. 17, 241–250 (2018).

Kwok, J. B. Role of epigenetics in Alzheimer’s and Parkinson’s disease. Epigenomics 2, 671–682 (2010).

Qazi, T. J., Quan, Z., Mir, A. & Qing, H. Epigenetics in Alzheimer’s Disease: Perspective of DNA Methylation. Molecular Neurobiology 2017 55:2 55, 1026–1044 (2017).

Mastroeni, D. et al. Epigenetic changes in Alzheimer’s disease: Decrements in DNA methylation. Neurobiol. Aging 31, 2025–2037 (2010).

Monteiro, A. R., Barbosa, D. J., Remião, F. & Silva, R. Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem. Pharmacol. 211, 115522 (2023).

Yokoyama, A. S., Rutledge, J. C. & Medici, V. DNA methylation alterations in Alzheimer’s disease. Environ. Epigenet. 3, (2017).

Chouliaras, L. et al. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer’s disease patients. Neurobiol. Aging 34, 2091–2099 (2013).

Bradley-Whitman, M. A. & Lovell, M. A. Epigenetic changes in the progression of Alzheimer’s disease. Mech. Ageing Dev. 134, 486–495 (2013).

Serrano-Pozo, A., Frosch, M. P., Masliah, E. & Hyman, B. T. Neuropathological Alterations in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).

Singh, S. K., Srivastav, S., Yadav, A. K., Srikrishna, S. & Perry, G. Overview of Alzheimer’s Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal Compounds. Oxid. Med. Cell. Longev. 2016, 7361613 (2016).

Spires-Jones, T. L. & Hyman, B. T. The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease. Neuron 82, 756–771 (2014).

Cras, P. et al. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proceedings of the National Academy of Sciences 88, 7552–7556 (1991).

Perl, D. P. Neuropathology of Alzheimer’s Disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77, 32–42 (2010).

Armstrong, R. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathol. (2009).

Tabaton, M. & Piccini, A. Role of water-soluble amyloid-β in the pathogenesis of Alzheimer’s disease. Int. J. Exp. Pathol. 86, 139–145 (2005).

Brion, J.-P. & Brion, J.-P. Neurofibrillary Tangles and Alzheimer’s Disease. Eur. Neurol. 40, 130–140 (1998).

Metaxas, A. & Kempf, S. J. Neurofibrillary tangles in Alzheimer’s disease: Elucidation of the molecular mechanism by immunohistochemistry and tau protein phospho-proteomics. Neural Regen. Res. 11, 1579–1581 (2016).

Overk, C. R. & Masliah, E. Pathogenesis of synaptic degeneration in Alzheimer’s disease and Lewy body disease. Biochem. Pharmacol. 88, 508–516 (2014).

Lleó, A. et al. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer’s Disease Cerebrospinal Fluid. Molecular & Cellular Proteomics 18, 546–560 (2019).

Tarawneh, R. et al. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurol. 73, 561–571 (2016).

Ito, F., Sono, Y. & Ito, T. Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxidative Stress in Diabetes, Atherosclerosis, and Chronic Inflammation. Antioxidants 2019, Vol. 8, Page 72 8, 72 (2019).

Forman, H. J. & Zhang, H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nature Reviews Drug Discovery 2021 20:9 20, 689–709 (2021).

Savelieff, M. G. et al. Development of multifunctional molecules as potential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the last decade. Chem. Rev. 119, 1221–1322 (2019).

Circu, M. L. & Aw, T. Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med. 48, 749–762 (2010).

Van Cauwenberghe, C., Van Broeckhoven, C. & Sleegers, K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genetics in Medicine 18, 421–430 (2016).

Khanahmadi, M., Farhud, D. & Malmir, M. Genetic of Alzheimer’s Disease: A Narrative Review Article. Iran. J. Public Health (2015).

Li, N. M. et al. Mutations of beta-amyloid precursor protein alter the consequence of Alzheimer’s disease pathogenesis. Neural Regen. Res. 14, 658–665 (2019).

Tcw, J. & Goate, A. M. Genetics of β-Amyloid Precursor Protein in Alzheimer’s Disease. Cold Spring Harb. Perspect. Med. 7, a024539 (2017).

Cai, Y., An, S. S. A. & Kim, S. Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders. Clin. Interv. Aging 10, 1163–1172 (2015).

Dai, M.-H. et al. The genes associated with early-onset Alzheimer’s disease. Oncotarget 9, 15132–15143 (2018).

Kelleher, R. J. & Shen, J. Presenilin-1 mutations and Alzheimer’s disease. Proceedings of the National Academy of Sciences 114, 629–631 (2017).

Walker, E. S., Martinez, M., Brunkan, A. L. & Goate, A. Presenilin 2 familial Alzheimer’s disease mutations result in partial loss of function and dramatic changes in Aβ 42/40 ratios. J. Neurochem. 92, 294–301 (2005).

Kim, J., Basak, J. M. & Holtzman, D. M. The Role of Apolipoprotein E in Alzheimer’s Disease. Neuron 63, 287–303 (2009).

Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology 2013 9:2 9, 106–118 (2013).

Giau, V. Van, Bagyinszky, E., An, S. S. A. & Kim, S. Y. Role of apolipoprotein E in neurodegenerative diseases. Neuropsychiatr. Dis. Treat. 11, 1723–1737 (2015).

Hu, Y. B., Dammer, E. B., Ren, R. J. & Wang, G. The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration. Transl. Neurodegener. 4, (2015).

Neefjes, J. & van der Kant, R. Stuck in traffic: an emerging theme in diseases of the nervous system. Trends Neurosci. 37, 66–76 (2014).

Tan, J. & Evin, G. Β-site APP-cleaving enzyme 1 trafficking and Alzheimer’s disease pathogenesis. J. Neurochem. 120, 869–880 (2012).

Wu, J. et al. Arc/Arg3.1 Regulates an Endosomal Pathway Essential for Activity-Dependent β-Amyloid Generation. Cell 147, 615 (2011).

Lamb, C. A., Dooley, H. C. & Tooze, S. A. Endocytosis and autophagy: Shared machinery for degradation. BioEssays 35, 34–45 (2013).

Tooze, S. A., Abada, A. & Elazar, Z. Endocytosis and Autophagy: Exploitation or Cooperation? Cold Spring Harb. Perspect. Biol. 6, (2014).

Huotari, J. & Helenius, A. Endosome maturation. EMBO J. 30, 3481–3500 (2011).

Diering, G. H. & Numata, M. Endosomal pH in neuronal signaling and synaptic transmission: Role of Na+/H+ exchanger NHE5. Front. Physiol. 4 JAN, 70666 (2014).

Verkhovskii, R. A. et al. Current Principles, Challenges, and New Metrics in pH-Responsive Drug Delivery Systems for Systemic Cancer Therapy. Pharmaceutics 15, (2023).

Villarroel-Campos, D., Gastaldi, L., Conde, C., Caceres, A. & Gonzalez-Billault, C. Rab-mediated trafficking role in neurite formation. J. Neurochem. 129, 240–248 (2014).

Laifenfeld, D. et al. Rab5 Mediates an Amyloid Precursor Protein Signaling Pathway That Leads to Apoptosis. The Journal of Neuroscience 27, 7141 (2007).

Hsu, V. W. & Prekeris, R. Transport at the recycling endosome. Curr. Opin. Cell Biol. 22, 528–534 (2010).

Li, X. & DiFiglia, M. The recycling endosome and its role in neurological disorders. Prog. Neurobiol. 97, 127–141 (2012).

Ulery, P. G. et al. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer’s disease. J. Biol. Chem. 275, 7410–7415 (2000).

Kang, D. E. et al. Modulation of amyloid beta-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Invest. 106, 1159–1166 (2000).

Rajendran, L. et al. Efficient inhibition of the Alzheimer’s disease beta-secretase by membrane targeting. Science 320, 520–523 (2008).

HS, K. et al. Carboxyl-terminal fragment of Alzheimer’s APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity. FASEB J. 14, 1508–1517 (2000).

Cataldo, A. M. et al. Aβ localization in abnormal endosomes: Association with earliest Aβ elevations in AD and Down syndrome. Neurobiol. Aging 25, 1263–1272 (2004).

Ling, D., Song, H. J., Garza, D., Neufeld, T. P. & Salvaterra, P. M. Abeta42-Induced Neurodegeneration via an Age-Dependent Autophagic-Lysosomal Injury in Drosophila. PLoS One 4, 4201 (2009).

Nixon, R. A. Endosome function and dysfunction in Alzheimer’s disease and other neurodegenerative diseases. Neurobiol. Aging 26, 373–382 (2005).

Cataldo, A. M., Barnett, J. L., Pieroni, C. & Nixon, R. A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer’s disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J. Neurosci. 17, 6142–6151 (1997).

Ginsberg, S. D. et al. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer’s disease progression. Biol. Psychiatry 68, 885–893 (2010).

Cataldo, A. M. et al. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer’s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am. J. Pathol. 157, 277–286 (2000).

Bonnet, U., Scherbaum, N. & Wiemann, M. The endogenous alkaloid harmane: Acidifying and activity-reducing effects on hippocampal neurons in vitro. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 362–367 (2008).

Majumdar, A., Capetillo-Zarate, E., Cruz, D., Gouras, G. K. & Maxfield, F. R. Degradation of Alzheimer’s amyloid fibrils by microglia requires delivery of ClC-7 to lysosomes. Mol. Biol. Cell 22, 1664 (2011).

Lee, J. H. et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell 141, 1146–1158 (2010).

Zhao, L. et al. Structural analysis of asparaginyl endopeptidase reveals the activation mechanism and a reversible intermediate maturation stage. Cell Research 2014 24:3 24, 344–358 (2014).

Forester, B. P. et al. Age-related changes in brain energetics and phospholipid metabolism. NMR Biomed. 23, 242–250 (2010).

Zhang, Z. et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat. Med. 20, 1254–1262 (2014).

Wolfe, D. M. et al. Autophagy failure in Alzheimer’s disease and the role of defective lysosomal acidification. Eur. J. Neurosci. 37, 1949–1961 (2013).

Chintapalli, V. R. et al. Transport proteins NHA1 and NHA2 are essential for survival, but have distinct transport modalities. Proc. Natl. Acad. Sci. U. S. A. 112, 11720–11725 (2015).

Fuster, D. G. & Alexander, R. T. Traditional and emerging roles for the SLC9 Na+/H+ exchangers. Pflugers Arch. 466, 61–76 (2014).

Windler, F. et al. The solute carrier SLC9C1 is a Na+/H+-exchanger gated by an S4-type voltage-sensor and cyclic-nucleotide binding. Nat. Commun. 9, (2018).

Huang, Y., Chen, W., Dotson, D. L., Beckstein, O. & Shen, J. Mechanism of pH-dependent activation of the sodium-proton antiporter NhaA. Nat. Commun. 7, (2016).

Maes, M., Rimon, A., Kozachkov-Magrisso, L., Friedler, A. & Padan, E. Revealing the Ligand Binding Site of NhaA Na+/H+ Antiporter and Its pH Dependence. J. Biol. Chem. 287, 38150 (2012).

Wakabayashi, S., Hisamitsu, T., Pang, T. & Shigekawa, M. Kinetic dissection of two distinct proton binding sites in Na+/H+ exchangers by measurement of reverse mode reaction. J. Biol. Chem. 278, 43580–43585 (2003).

Wakabayashi, S., Hisamitsu, T., Pang, T. & Shigekawa, M. Mutations of Arg440 and Gly455/Gly456 oppositely change pH sensing of Na+/H+ exchanger 1. J. Biol. Chem. 278, 11828–11835 (2003).

Touret, N., Poujeol, P. & Counillon, L. Second-site revertants of a low-sodium-affinity mutant of the Na+/H+ exchanger reveal the participation of TM4 into a highly constrained sodium-binding site. Biochemistry 40, 5095–5101 (2001).

Slepkov, E. R., Rainey, J. K., Sykes, B. D. & Fliegel, L. Structural and functional analysis of the Na+/H+ exchanger. Biochem. J. 401, 623–633 (2007).

Omasits, U., Ahrens, C. H., Müller, S. & Wollscheid, B. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics 30, 884–886 (2014).

Miyazaki, E., Sakaguchi, M., Wakabayashi, S., Shigekawa, M. & Mihara, K. NHE6 protein possesses a signal peptide destined for endoplasmic reticulum membrane and localizes in secretory organelles of the cell. J. Biol. Chem. 276, 49221–49227 (2001).

Numata, M., Petrecca, K., Lake, N. & Orlowski, J. Identification of a mitochondrial Na+/H+ exchanger. J. Biol. Chem. 273, 6951–6959 (1998).

Ohgaki, R., Fukura, N., Matsushita, M., Mitsui, K. & Kanazawa, H. Cell surface levels of organellar Na+/H+ exchanger isoform 6 are regulated by interaction with RACK1. J. Biol. Chem. 283, 4417–4429 (2008).

Pulakat, L. et al. Ligand-dependent complex formation between the Angiotensin II receptor subtype AT2 and Na+/H+ exchanger NHE6 in mammalian cells. Peptides (N.Y.). 26, 863–873 (2005).

Gao, L. & Zucker, I. H. AT2 receptor signaling and sympathetic regulation. Curr. Opin. Pharmacol. 11, 124–130 (2011).

Gendron, L., Payet, M. D. & Gallo-Payet, N. The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. J. Mol. Endocrinol. 31, 359–372 (2003).

Guimond, M. O. & Gallo-Payet, N. How does angiotensin AT(2) receptor activation help neuronal differentiation and improve neuronal pathological situations? Front. Endocrinol. (Lausanne). 3, (2012).

Hill, J. K. et al. Vestibular Hair Bundles Control pH with (Na+, K+)/H+ Exchangers NHE6 and NHE9. The Journal of Neuroscience 26, 9944 (2006).

Liu, L., Schlesinger, P. H., Slack, N. M., Friedman, P. A. & Blair, H. C. High capacity Na+/H+ exchange activity in mineralizing osteoblasts. J. Cell. Physiol. 226, 1702–1712 (2011).

Lein, E. S. et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445, 168–176 (2007).

Deane, E. C. et al. Enhanced recruitment of endosomal Na+/H+ exchanger NHE6 into Dendritic spines of hippocampal pyramidal neurons during NMDA receptor-dependent long-term potentiation. J. Neurosci. 33, 595–610 (2013).

Park, M. et al. Plasticity-induced growth of dendritic spines by exocytic trafficking from recycling endosomes. Neuron 52, 817–830 (2006).

Park, M., Penick, E. C., Edwards, J. G., Kauer, J. A. & Ehlers, M. D. Recycling endosomes supply AMPA receptors for LTP. Science 305, 1972–1975 (2004).

Chao, M. V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci. 4, 299–309 (2003).

Huang, E. J. & Reichardt, L. F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 24, 677–736 (2001).

Rex, C. S. et al. Brain-Derived Neurotrophic Factor Promotes Long-Term Potentiation-Related Cytoskeletal Changes in Adult Hippocampus. The Journal of Neuroscience 27, 3017 (2007).

Koleske, A. J. Molecular mechanisms of dendrite stability. Nat. Rev. Neurosci. 14, 536–550 (2013).

Das, U. et al. Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron 79, 447–460 (2013).

Mellman, I. The importance of being acid: the role of acidification in intracellular membrane traffic. Journal of Experimental Biology 172, 39–45 (1992).

Kondapalli, K. C., Prasad, H. & Rao, R. An inside job: How endosomal Na+ /H+ exchangers link to autism and neurological disease. Front. Cell. Neurosci. 8, 172 (2014).

Ohgaki, R., Van Ijzendoorn, S. C. D., Matsushita, M., Hoekstra, D. & Kanazawa, H. Organellar Na+/H+ exchangers: Novel players in organelle pH regulation and their emerging functions. Biochemistry 50, 443–450 (2011).

Brett, C. L., Wei, Y., Donowitz, M. & Rao, R. Human Na+/H+ exchanger isoform 6 is found in recycling endosomes of cells, not in mitochondria. Am. J. Physiol. Cell Physiol. 282, (2002).

Kondapalli, K. C., Prasad, H. & Rao, R. An inside job: how endosomal Na(+)/H(+) exchangers link to autism and neurological disease. Front. Cell. Neurosci. 8, (2014).

Brett, C. L., Tukaye, D. N., Mukherjee, S. & Rao, R. The yeast endosomal Na+(K+)/H+ exchanger Nhx1 regulates cellular pH to control vesicle trafficking. Mol. Biol. Cell 16, 1396–1405 (2005).

Xinhan, L. et al. Na+/H+ exchanger isoform 6 (NHE6/SLC9A6) is involved in clathrin-dependent endocytosis of transferrin. Am. J. Physiol. Cell Physiol. 301, (2011).

Futai, M. et al. Luminal Acidification of Diverse Organelles by V-ATPase in Animal Cells. Journal of Experimental Biology 203, 107–116 (2000).

Choquet, D. & Triller, A. The Dynamic Synapse. Neuron 80, 691–703 (2013).

Zhao, H. et al. Emerging roles of Na+/H+ exchangers in epilepsy and developmental brain disorders. Prog. Neurobiol. 138–140, 19–35 (2016).

Verpelli, C., Galimberti, I., Gomez-Mancilla, B. & Sala, C. Molecular basis for prospective pharmacological treatment strategies in intellectual disability syndromes. Dev. Neurobiol. 74, 197–206 (2014).

Müller, U. C., Deller, T. & Korte, M. Not just amyloid: physiological functions of the amyloid precursor protein family. Nature Reviews Neuroscience 2017 18:5 18, 281–298 (2017).

APP - NCBI Gene. APP. https://www.ncbi.nlm.nih.gov/gene/351.

APP, KEGG ORTHOLOGY: K04520. https://www.kegg.jp/entry/K04520.

Haass, C., Kaether, C., Thinakaran, G. & Sisodia, S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2, (2012).

Hefter, D. et al. Amyloid Precursor Protein Protects Neuronal Network Function after Hypoxia via Control of Voltage-Gated Calcium Channels. J. Neurosci. 36, 8356–8371 (2016).

Mockett, B. G., Richter, M., Abraham, W. C. & Mülle, U. C. Therapeutic Potential of Secreted Amyloid Precursor Protein APPsα. Front. Mol. Neurosci. 10, (2017).

Sasaguri, H. et al. APP mouse models for Alzheimer’s disease preclinical studies. EMBO J. 36, 2473–2487 (2017).

Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).

Hefter, D., Ludewig, S., Draguhn, A. & Korte, M. Amyloid, APP, and Electrical Activity of the Brain. Neuroscientist 26, 231–251 (2020).

PSEN1 - NCBI Gene. PSEN1. https://www.ncbi.nlm.nih.gov/gene/5663.

PSEN1, KEGG ORTHOLOGY: K04505. https://www.kegg.jp/entry/K04505+K04522.

Yang, Y., Bagyinszky, E. & An, S. S. A. Presenilin-1 (PSEN1) Mutations: Clinical Phenotypes beyond Alzheimer’s Disease. Int. J. Mol. Sci. 24, (2023).

Chen, Q. & Schubert, D. Presenilin-interacting proteins. Expert Rev. Mol. Med. 4, 1–18 (2002).

Czech, C., Tremp, G. & Pradier, L. Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms. Prog. Neurobiol. 60, 363–384 (2000).

Kelleher, R. J. & Shen, J. Presenilin-1 mutations and Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A. 114, 629 (2017).

IRS1 - NCBI Gene. IRS1 insulin receptor substrate 1 [Homo sapiens (human)] - Gene - NCBI. https://www.ncbi.nlm.nih.gov/gene/3667.

IRS1, KEGG ORTHOLOGY: K16172. https://www.kegg.jp/entry/K16172+K07187+K17445+K17446.

Machado-Neto, J. A. et al. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics (Sao Paulo) 73, (2018).

Yong, H. L. & White, M. F. Insulin receptor substrate proteins and diabetes. Arch. Pharm. Res. 27, 361–370 (2004).

Sun, X. J. et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352, 73–76 (1991).

White, M. F., Maron, R. & Kahn, C. R. Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 318, 183–186 (1985).

CSNK1E - NCBI Gene. CSNK1E casein kinase 1 epsilon [Homo sapiens (human)] - Gene - NCBI. https://www.ncbi.nlm.nih.gov/gene/1454.

CSNK1E, KEGG ORTHOLOGY: K08960. https://www.kegg.jp/entry/K08960.

Ko, C. H. & Takahashi, J. S. Molecular components of the mammalian circadian clock. Hum. Mol. Genet. 15 Spec No 2, (2006).

Klingaman, E. A., Palmer-Bacon, J., Bennett, M. E. & Rowland, L. M. Sleep Disorders Among People With Schizophrenia: Emerging Research. Curr. Psychiatry Rep. 17, (2015).

Pritchett, D. et al. Evaluating the links between schizophrenia and sleep and circadian rhythm disruption. J. Neural Transm. (Vienna) 119, 1061–1075 (2012).

Pinacho, R. et al. Altered CSNK1E, FABP4 and NEFH protein levels in the dorsolateral prefrontal cortex in schizophrenia. Schizophr. Res. 177, 88–97 (2016).

Schwab, C. et al. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol. Aging 21, 503–510 (2000).

Gilfillan, G. D. et al. SLC9A6 Mutations Cause X-Linked Mental Retardation, Microcephaly, Epilepsy, and Ataxia, a Phenotype Mimicking Angelman Syndrome. Am. J. Hum. Genet. 82, 1003–1010 (2008).

Pescosolido, M. F. et al. Genetic and phenotypic diversity of NHE6 mutations in Christianson syndrome. Ann. Neurol. 76, 581–593 (2014).

Garbern, J. Y. et al. A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition. Brain 133, 1391–1402 (2010).

Jiao, J. P. et al. Missense variants in SLC9A6 cause partial epilepsy without neurodevelopmental delay. Orphanet J. Rare Dis. 20, 380 (2025).

Lan, Y. et al. Case Report: Christianson Syndrome Caused by SLC9A6 Mutation: From Case to Genotype-Phenotype Analysis. Front. Genet. 12, (2021).

Prasad, H. Genes for endosomal pH regulators NHE6 and NHE9 are dysregulated in the substantia nigra in Parkinson’s disease. Gene 927, 148737 (2024).

Okochi, R., Nihei, Y. & Ito, D. NDPACX: a newly defined X-linked Parkinsonian syndrome associated with SLC9A6 hemizygote mutation. Brain Commun. 7, (2025).

Xian, X. et al. Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer’s disease. Elife 7, (2018).

Pohlkamp, T. et al. NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces Amyloid plaque load. Elife 10, (2021).

Huang, N. et al. Targeting the HDAC4-NHE6-endosomal pH axis restores amyloid-β clearance and cognitive function in Alzheimer’s disease mice. J. Nanobiotechnology 24, (2026).

Masereel, B., Pochet, L. & Laeckmann, D. An overview of inhibitors of Na+/H+ exchanger. Eur. J. Med. Chem. 38, 547–554 (2003).

Uria-Avellanal, C. & Robertson, N. J. Na+/H+ Exchangers and Intracellular pH in Perinatal Brain Injury. Transl. Stroke Res. 5, 79–98 (2014).

Pedersen, S. F. & Counillon, L. The SLC9A-C mammalian Na+/H+ exchanger family: Molecules, mechanisms, and physiology. Physiol. Rev. 99, 2015–2113 (2019).

Azzopard, D. et al. Prognosis of newborn infants with hypoxic-ischemic brain injury assessed by phosphorus magnetic resonance spectroscopy. Pediatr. Res. 25, 445–451 (1989).

Blumberg, R. M., Cady, E. B., Wigglesworth, J. S., McKenzie, J. E. & Edwards, A. D. Relation between delayed impairment of cerebral energy metabolism and infarction following transient focal hypoxia-ischaemia in the developing brain. Exp. Brain Res. 113, 130–137 (1997).

Hope, P. L. et al. CEREBRAL ENERGY METABOLISM STUDIED WITH PHOSPHORUS NMR SPECTROSCOPY IN NORMAL AND BIRTH-ASPHYXIATED INFANTS. The Lancet 324, 366–370 (1984).

Robertson, N. J. et al. Cerebral intracellular lactic alkalosis persisting months after neonatal encephalopathy measured by magnetic resonance spectroscopy. Pediatr. Res. 46, 287–296 (1999).

Robertson, N. J., Cowan, F. M., Cox, I. J. & Edwards, A. D. Brain alkaline intracellular pH after neonatal encephalopathy. Ann. Neurol. 52, 732–742 (2002).

Barkovich, A. J. et al. MR Imaging, MR Spectroscopy, and Diffusion Tensor Imaging of Sequential Studies in Neonates with Encephalopathy. AJNR Am. J. Neuroradiol. 27, 533 (2006).

Cowan, F. et al. Origin and timing of brain lesions in term infants with neonatal encephalopathy. Lancet 361, 736–742 (2003).

Vornov, J. J., Thomas, A. G. & Jo, D. Protective effects of extracellular acidosis and blockade of sodium/hydrogen ion exchange during recovery from metabolic inhibition in neuronal tissue culture. J. Neurochem. 67, 2379–2389 (1996).

Matsumoto, Y. et al. Na+/H+ Exchanger Inhibitor, SM-20220, Is Protective Against Excitotoxicity in Cultured Cortical Neurons. Stroke 35, 185–190 (2004).

Lee, C. et al. A two-domain elevator mechanism for sodium/proton antiport. Nature 501, 573–577 (2013).

Phillis, J. W., Ren, J. & O’Regan, M. H. Inhibition of Na+/H+ exchange by 5-(N-ethyl-N-isopropyl)-amiloride reduces free fatty acid efflux from the ischemic reperfused rat cerebral cortex. Brain Res. 884, 155–162 (2000).

Pilitsis, J. G., Diaz, F. G., O’Regan, M. H. & Phillis, J. W. Inhibition of Na+/H+ exchange by SM-20220 attenuates free fatty acid efflux in rat cerebral cortex during ischemia-reperfusion injury. Brain Res. 913, 156–158 (2001).

Hwang, I. K. et al. Late expression of Na+/H+ exchanger 1 (NHE1) and neuroprotective effects of NHE inhibitor in the gerbil hippocampal CA1 region induced by transient ischemia. Exp. Neurol. 212, 314–323 (2008).

Cengiz, P. et al. Inhibition of Na+/H+ exchanger isoform 1 is neuroprotective in neonatal hypoxic ischemic brain injury. Antioxid. Redox Signal. 14, 1803–1813 (2011).

Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).